Skip to main content
. 2020 May 4;123(1):38–45. doi: 10.1038/s41416-020-0847-1

Table 5.

Hazard ratios (HR) with 95% confidence intervals (CI) of mortality comparing patients with hepatocellular carcinoma undergoing non-surgical treatment in Oulu University Hospital 1983–2018.

Negative budding (n = 131) HR (95% CI) Positive budding (n = 81) HR (95% CI) P value High TSR (n = 172) HR (95% CI) Low TSR (n = 40) HR (95% CI) P value
3-year overall mortality
 Crudea 1 (reference) 0.70 (0.51–0.97) 0.031 1 (reference) 1.06 (0.72–1.57) 0.756
 Adjustedb 1 (reference) 0.81 (0.58–1.15) 0.241 1 (reference) 1.01 (0.66–1.55) 0.965
3-year disease-specific mortality
 Crudea 1 (reference) 0.64 (0.44–0.93) 0.020 1 (reference) 0.97 (0.61–1.52) 0.884
 Adjustedb 1 (reference) 0.74 (0.50–1.11) 0.143 1 (reference) 0.89 (0.54–1.47) 0.643

Follow-up ended on December 31, 2017. In patients operated in 2018, follow-up ended 30 days after surgery.

aCrude was adjusted with treatment (local ablation/TACE/palliative).

bAdjustment for age (continuous), sex (female/male), Charlson Comorbidity Index (0–1, 2 or more), stage (1, 2 or more), cirrhosis (no/yes), year of surgery/diagnosis (1983–2005 and 2006–2018), Child–Pugh index (A, B or C) and tumour grade (1–2 and 3) (local ablation/TACE/palliative).